Leerink Partnrs Has Pessimistic View of JANX Q3 Earnings

Janux Therapeutics, Inc. (NASDAQ:JANX) – Analysts at Leerink Partnrs reduced their Q3 2025 EPS estimates for shares of Janux Therapeutics in a research note issued to investors on Monday, August 11th. Leerink Partnrs analyst J. La. Rosa now expects that the company will post earnings of ($0.59) per share for the quarter, down from their prior forecast of ($0.54). The consensus estimate for Janux Therapeutics’ current full-year earnings is ($1.38) per share. Leerink Partnrs also issued estimates for Janux Therapeutics’ Q4 2025 earnings at ($1.22) EPS, FY2025 earnings at ($2.74) EPS, FY2026 earnings at ($5.50) EPS, FY2027 earnings at ($6.22) EPS, FY2028 earnings at ($4.88) EPS and FY2029 earnings at ($2.77) EPS.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.07).

Separately, Raymond James Financial started coverage on shares of Janux Therapeutics in a report on Friday, July 11th. They set an “outperform” rating and a $65.00 price target for the company. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $91.89.

Janux Therapeutics Price Performance

JANX stock opened at $25.11 on Thursday. Janux Therapeutics has a 52-week low of $21.97 and a 52-week high of $71.71. The company has a 50-day moving average of $24.61 and a two-hundred day moving average of $28.42. The stock has a market capitalization of $1.51 billion, a price-to-earnings ratio of -13.95 and a beta of 2.86.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in JANX. GAMMA Investing LLC raised its position in shares of Janux Therapeutics by 1,574.0% during the first quarter. GAMMA Investing LLC now owns 1,674 shares of the company’s stock valued at $45,000 after buying an additional 1,574 shares during the last quarter. US Bancorp DE raised its position in shares of Janux Therapeutics by 2,402.9% during the first quarter. US Bancorp DE now owns 1,727 shares of the company’s stock valued at $47,000 after buying an additional 1,658 shares during the last quarter. Russell Investments Group Ltd. raised its position in shares of Janux Therapeutics by 77.7% during the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock valued at $54,000 after buying an additional 442 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in Janux Therapeutics in the fourth quarter valued at about $59,000. Finally, FNY Investment Advisers LLC increased its stake in Janux Therapeutics by 6,928.6% in the first quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company’s stock valued at $66,000 after acquiring an additional 2,425 shares during the period. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.